<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>20(1)</volume><submitter>Garcia A</submitter><funding>GlaxoSmithKline</funding><pubmed_abstract>The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66-80 years, starting with 80 years. However, the risk of herpes zoster (HZ) increases significantly from 50 years. We estimated the public health impact (PHI) of vaccinating adults ≥50 years in Spain versus no vaccination, using a Markov model adapted to the Spanish setting. The model simulated a hypothetical ≥50 years cohort over a lifetime, with inputs from Spanish publications, databases, or publications from other countries where Spanish data were unavailable. Base case inputs included 67.7% RZV coverage and 61.1% second dose compliance. Outputs included clinical outcomes avoided, healthcare resourc</pubmed_abstract><journal>Human vaccines &amp; immunotherapeutics</journal><pagination>2366353</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC11210909</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain.</pubmed_title><pmcid>PMC11210909</pmcid><pubmed_authors>Vallejo-Aparicio LA</pubmed_authors><pubmed_authors>Cambronero Martinez R</pubmed_authors><pubmed_authors>Garcia A</pubmed_authors></additional><is_claimable>false</is_claimable><name>The public health impact of recombinant herpes zoster vaccination in adults over 50 years in Spain.</name><description>The recombinant zoster vaccine (RZV) is included in the Spanish National Immunisation Programme for adults 65 years of age (years), with a potential progressive catch-up program for adults 66-80 years, starting with 80 years. However, the risk of herpes zoster (HZ) increases significantly from 50 years. We estimated the public health impact (PHI) of vaccinating adults ≥50 years in Spain versus no vaccination, using a Markov model adapted to the Spanish setting. The model simulated a hypothetical ≥50 years cohort over a lifetime, with inputs from Spanish publications, databases, or publications from other countries where Spanish data were unavailable. Base case inputs included 67.7% RZV coverage and 61.1% second dose compliance. Outputs included clinical outcomes avoided, healthcare resourc</description><dates><release>2024-01-01T00:00:00Z</release><publication>2024 Dec</publication><modification>2025-04-19T18:33:19.89Z</modification><creation>2025-04-19T18:33:19.89Z</creation></dates><accession>S-EPMC11210909</accession><cross_references><pubmed>38925145</pubmed><doi>10.1080/21645515.2024.2366353</doi></cross_references></HashMap>